BENJAMIN T STEVENS
Broker in Cambridge, MA
License number
Massachusetts 112815
Issued Date
Mar 1, 1989
Expiration Date
Jan 19, 1991
Type
Salesperson
Address
Address
Cambridge, MA 02139
Professional information
Principal Scientist At Pfizer
Position:
Principal Scientist at Pfizer
Location:
Cambridge, Massachusetts
Industry:
Pharmaceuticals
Work:
Pfizer
- Cambridge, MA since Sep 2008
-
Principal Scientist
Merck & Co.
- Rahway, New Jersey Dec 2006 - Sep 2008
-
Senior Research Chemist
University of Rochester
- Rochester, New York Area May 1999 - Aug 1999
-
REU Intern
Keefe, Bruyette and Woods
Jun 1998 - Aug 1998
-
Fixed Income Department Intern
Education:
The Johns Hopkins University 2008 - 2012
M.P.H., Public Health University of Pittsburgh 2002 - 2006
PhD, Organic Chemistry University of Rochester 1997 - 2002
BS/MS, Biochemistry/Chemistry
M.P.H., Public Health University of Pittsburgh 2002 - 2006
PhD, Organic Chemistry University of Rochester 1997 - 2002
BS/MS, Biochemistry/Chemistry
Skills:
Medicinal Chemistry, Drug Discovery, Organic Synthesis, Drug Design, Parallel Synthesis, Organic Chemistry, LC-MS, Heterocyclic Chemistry, NMR, HPLC, Synthetic Organic Chemistry, ADME, Chemistry, Drug Development, Chromatography, Purification, Drug Metabolism, Analytical Chemistry, Pharmaceutical Research, Pharmaceutical Industry, In Vitro, Assay Development, Biomarkers, Pharmacology, Biochemistry
Languages:
English
Awards:
MPH Capstone Proposal Award
Johns Hopkins Bloomberg School of Public Health
Capstone proposal "Strategies for the Discovery of Novel Anti-Infective Agents” under advisement of Prof. Jürgen Bosch and Prof. Randy Bryant.
Organic Division Pre-doctoral Fellowship Sponsored by Sanofi-Aventis
American Chemical Society
American Heart Association Pre-doctoral Fellowship
American Heart Association
Graduate Excellence Fellowship
University of Pittsburgh
Bayer Fellowship (Chair’s Scholar Award)
University of Pittsburgh
Boehringer Masters Scholarship
University of Rochester
Golden Key Honor Society
Golden Key
NSF Sponsored REU Program
University of Rochester
Meliora Grant
University of Rochester
Bauch and Lomb Scholarship for Excellence in Science
University of Rochester
Johns Hopkins Bloomberg School of Public Health
Capstone proposal "Strategies for the Discovery of Novel Anti-Infective Agents” under advisement of Prof. Jürgen Bosch and Prof. Randy Bryant.
Organic Division Pre-doctoral Fellowship Sponsored by Sanofi-Aventis
American Chemical Society
American Heart Association Pre-doctoral Fellowship
American Heart Association
Graduate Excellence Fellowship
University of Pittsburgh
Bayer Fellowship (Chair’s Scholar Award)
University of Pittsburgh
Boehringer Masters Scholarship
University of Rochester
Golden Key Honor Society
Golden Key
NSF Sponsored REU Program
University of Rochester
Meliora Grant
University of Rochester
Bauch and Lomb Scholarship for Excellence in Science
University of Rochester
Glucagon Receptor Modulators
US Patent:
2013029, Nov 7, 2013
Filed:
Jul 3, 2013
Appl. No.:
13/934322
Inventors:
Mary Theresa Didiuk - Madison CT, US
Kevin James Filipski - Reading MA, US
Angel Guzman-Perez - Belmont MA, US
Esther Cheng Yin Lee - Shirley MA, US
Jeffrey Allen Pfefferkorn - Acton MA, US
Benjamin Dawson Stevens - Cambridge MA, US
Meihua Mike Tu - Acton MA, US
Kevin James Filipski - Reading MA, US
Angel Guzman-Perez - Belmont MA, US
Esther Cheng Yin Lee - Shirley MA, US
Jeffrey Allen Pfefferkorn - Acton MA, US
Benjamin Dawson Stevens - Cambridge MA, US
Meihua Mike Tu - Acton MA, US
International Classification:
C07D 487/04, C07D 401/12, C07D 231/12, C07D 401/04, C07D 231/18, C07D 405/14, C07D 249/08, C07D 261/08, C07D 231/56, C07D 403/12, C07D 401/14, C07D 233/64, C07D 207/34
US Classification:
514275, 5483435, 514400, 5462754, 514341, 5483771, 514406, 5462761, 514407, 548561, 514427, 5483031, 514393, 5482658, 514383, 548249, 514378, 544331, 546256, 514333
Abstract:
The present invention provides a compound of Formula (I)or a pharmaceutically acceptable salt thereof wherein R, R, R, A, A, A, A, L, B, B, Band Bare as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.